Farther Finance Advisors LLC Boosts Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• Farther Finance Advisors increased its Bristol Myers Squibb stake by 28.5% in the third quarter, owning 190,235 shares valued at approximately $12.1 million. Institutional investors collectively hold 76.41% of BMY’s shares.
• Bristol Myers Squibb reported quarterly EPS of $2.04, beating estimates of $1.60, while revenue rose 5.7% year over year to $12.97 billion. The company also announced a quarterly dividend of $0.63 per share, representing a 4.2% annualized yield.
• Analyst sentiment remains moderately bullish, with an average price target of $66.72, although recent targets ranged from $53 to $75. The company’s ZENBEXUS multiple-myeloma results provided a positive pipeline catalyst, while Cantor Fitzgerald and Leerink Partners issued more cautious views.

Farther Finance Advisors LLC lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 190,235 shares of the biopharmaceutical company's stock after buying an additional 42,218 shares during the period. Farther Finance Advisors LLC's holdings in Bristol Myers Squibb were worth $12,093,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of BMY. Boltwood Capital Management lifted its stake in Bristol Myers Squibb by 2.5% during the 3rd quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company's stock valued at $443,000 after acquiring an additional 170 shares in the last quarter. KCM Investment Advisors LLC grew its stake in shares of Bristol Myers Squibb by 0.8% in the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company's stock worth $1,126,000 after acquiring an additional 174 shares in the last quarter. Sandy Cove Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company's stock valued at $227,000 after purchasing an additional 176 shares during the last quarter. Investment Research Partners LLC lifted its position in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company's stock valued at $708,000 after purchasing an additional 179 shares in the last quarter. Finally, Key Financial Inc boosted its holdings in Bristol Myers Squibb by 2.4% during the first quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company's stock worth $482,000 after purchasing an additional 183 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: ZENBEXUS delivered a significant Phase 3 result. Bristol Myers said the iberdomide combination with daratumumab and dexamethasone produced superior progression-free survival versus standard of care in relapsed or refractory multiple myeloma, cutting the risk of disease progression or death by 51%. The result strengthens the company’s pipeline and could support broader use of the therapy. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
• Positive Sentiment: ZENBEXUS met the primary progression-free-survival endpoint in a pivotal trial. The update adds evidence behind the drug’s commercial potential following an earlier approval tied to achievement of another endpoint in the same study. BMS Zenbexus Meets PFS Endpoint
• Positive Sentiment: Analysts expect another earnings beat. Coverage points to Bristol Myers’ history of exceeding estimates and a favorable combination of earnings expectations and estimate revisions, though this is a forecast rather than a reported result. Will Bristol Myers Beat Estimates Again
• Positive Sentiment: Growth assets and income appeal remain part of the bullish case. Coverage highlights Reblozyl’s sales growth and potential new indications, a Camzyos label expansion, and BMY’s relatively attractive value and dividend profile as offsets to declining legacy-drug sales.
• Neutral Sentiment: ZENBEXUS’ ultimate impact will depend on regulatory steps, commercial uptake and competitive positioning in multiple myeloma.
• Negative Sentiment: Cantor Fitzgerald lowered its BMY price target from $59 to $53 and maintained a Neutral rating. The reduced target signals limited near-term upside in the firm’s view and is the clearest negative analyst catalyst in the latest coverage.

Wall Street Analysts Forecast Growth

BMY has been the subject of a number of recent analyst reports. Roth Capital began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price objective for the company. Cantor Fitzgerald cut their target price on Bristol Myers Squibb from $59.00 to $53.00 and set a "neutral" rating on the stock in a research note on Thursday. Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 27th. Guggenheim reaffirmed a "buy" rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, Leerink Partners lowered Bristol Myers Squibb from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $73.00 to $59.00 in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $66.72.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $59.51 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market cap of $121.57 billion, a price-to-earnings ratio of 13.11, a P/E/G ratio of 0.28 and a beta of 0.19. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The firm's 50-day simple moving average is $64.27 and its two-hundred day simple moving average is $60.28.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb's quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb's portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.